Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer

被引：2
|
作者：
Qiu, M. [1 ]
Wei, G. [1 ]
Leng, W. [1 ]
Cao, P. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, West China Sch Med, Dept Colorectal Canc Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
624P
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 50 条
  • [31] TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
    Boku, Shogen
    Satake, Hironaga
    Ohta, Takashi
    Mitani, Seiichiro
    Kawakami, Kentaro
    Suzuki, Yozo
    Matsumoto, Toshihiko
    Terazawa, Tetsuji
    Yamazaki, Eiki
    Hasegawa, Hiroko
    Ikoma, Tatsuki
    Uemura, Mamoru
    Yamaguchi, Toshifumi
    Naito, Atsushi
    Ishizuka, Yasunobu
    Kurokawa, Yukinori
    Sakai, Daisuke
    Kawakami, Hisato
    Shimokawa, Toshio
    Tsujinaka, Toshimasa
    Kato, Takeshi
    Satoh, Taroh
    Kagawa, Yoshinori
    FUTURE ONCOLOGY, 2023, 18 (38) : 4153 - 4160
  • [32] Molecular characterization and subsequent treatments after encorafenib-cetuximab plus /- binimetinib in BRAF V600E-mutated colorectal cancer.
    Ros Montana, Javier
    Navarro, Victor
    Comas, Raquel
    Garcia, Ariadna
    Saoudi Gonzalez, Nadia
    Baraibar, Iosune
    Salva, Francesc
    Vivancos, Ana
    Tabernero, Josep
    Elez, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study
    Chen, Yijiao
    Zhu, Dexiang
    Yu, Yiyi
    Chang, Wenju
    Ye, Lechi
    Feng, Qingyang
    Xu, Pingping
    Chen, Miao
    Ji, Meiling
    Wei, Ye
    Liu, Tianshu
    Xu, Jianmin
    CLINICAL COLORECTAL CANCER, 2024, 23 (04)
  • [34] The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
    Wang, Zhan
    Ye, Chen-Yang
    Zhou, Wen-Li
    Wang, Miao-Miao
    Dai, Wei-Ping
    Zheng, Jingjing
    Zang, Yuan-Sheng
    ONCOTARGETS AND THERAPY, 2020, 13 : 11849 - 11853
  • [35] Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report
    Goto, Keisuke
    Yoshikawa, Shusuke
    Kiyohara, Yoshio
    Kukita, Yoji
    Miura, Keiko
    Oishi, Takuma
    JOURNAL OF CUTANEOUS PATHOLOGY, 2022, 49 (04) : 393 - 398
  • [36] Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
    Yaeger, Rona D.
    Cercek, Andrea
    O'Reilly, Eileen Mary
    Reidy, Diane Lauren
    Kemeny, Nancy E.
    Wolinsky, Tamar
    Gollub, Marc J.
    Lacouture, Mario E.
    Rosen, Neal
    Vakiani, Efsevia
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] Metastatic BRAF V600E-Mutated Adenocarcinoma of the Lung Presenting as Extreme Neutrophilia and Eosinophilia
    Muhammad, Azharuddin
    Nair, Hari K.
    Tulpule, Sunil
    Khan, Adnan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [38] Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
    Boccaccino, A.
    Borelli, B.
    Intini, R.
    Antista, M.
    Bensi, M.
    Rossini, D.
    Passardi, A.
    Tamberi, S.
    Giampieri, R.
    Antonuzzo, L.
    Noto, L.
    Roviello, G.
    Zichi, C.
    Salati, M.
    Puccini, A.
    Noto, C.
    Parisi, A.
    Rihawi, K.
    Persano, M.
    Crespi, V
    Libertini, M.
    Giordano, M.
    Moretto, R.
    Lonardi, S.
    Cremolini, C.
    ESMO OPEN, 2022, 7 (03)
  • [39] BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer
    Di Nicolantonio, F.
    Martini, M.
    Molinari, F.
    Bianchi, A. Sartore
    Arena, S.
    Saletti, P.
    Mazzucchelli, L.
    Frattini, M.
    Siena, S.
    Bardelli, A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
  • [40] Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
    Arance, A. M.
    Berrocal, A.
    Lopez-Martin, J. A.
    de la Cruz-Merino, L.
    Soriano, V.
    Martin Algarra, S.
    Alonso, L.
    Cerezuela, P.
    La Orden, B.
    Espinosa, E.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (11): : 1147 - 1157
12345